To include your compound in the COVID-19 Resource Center, submit it here.

FDA extends review for Remicade in pediatric UC

FDA extended the review period by three months for Remicade infliximab in pediatric

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE